Morning Trend | JACOBIO-B reduces volume and grinds at the bottom, will an upward opportunity emerge?
JACOBIO-B (1167.HK) consolidated with reduced volume yesterday, with the stock price operating within a limited range, repeatedly testing the resistance at HKD 8.08 without success. The biotechnology sector is still in a high valuation correction phase, and overall market risk appetite has declined. The company has had no significant new drug development or financing movements in the past two weeks, leading to a cautious stance among main investors, with a focus on range trading and active arbitrage. Although acquisition news in the sector has attracted attention, its effects have not transmitted to JACOBIO. The technical chart shows a continuation of the MACD death cross, with short-term moving averages trending downward, and selling pressure remains persistent. If there is a rebound, trapped positions at high levels may actively seek to break even, making the market prone to repeated washout characteristics. In the short term, if there are new drug clinical news or industry mergers and acquisitions, it may ignite sentiment; otherwise, right-side capital operations need to remain cautious, and risk exposure must still be strictly controlled, with aggressive accumulation not recommended without strong signals
Technical Forecast·
